ArticleNPJ precision oncology2025
Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of prognostic risk factors and construction of nomograms for elderly patients with stage III-IV endometrioid endometrial carcinoma: a study based on the SEER database.Translational cancer research · 2026Article
- Oxidative stress-mediated responses in endometrial cancer cells: contrasting effects of doxorubicin and menadione.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Endometrial carcinoma (EC), the most common gynecologic cancer type in developed countries, encompasses four molecular subtypes (POLEmut, MMRd, p53abn, and NSMP) that have prognostic values and guide treatment decisions. Additionally, dual loss of ARID1A and ARID1B (referred to as ARID1A/B) characterizes a significant portion of dedifferentiated/undifferentiated EC (DD/UDEC), a rare but highly aggressive subtype of EC. To advance the translational research for ECs, we analyzed the genomic features of a panel of 39 EC cell lines, leading to the identification of cell lines representing each of these EC molecular subtype. Histologic and immunohistochemical analyses of xenografted tumors from these cell lines confirmed their resemblance of cognate primary EC molecular subtypes. Further investigation of the publicly available genome-wide CRISPR screen data for EC cell lines identified multiple specific genetic dependencies in MMRd, p53abn, and ARID1A/B-dual deficient EC cell lines. Particularly, ARID1A/B-dual deficient DD/UDEC cells selectively rely on mitochondrial oxidative phosphorylation in vitro and in vivo. Therefore, through molecular subtyping of EC cell lines and subsequent characterization of molecular subtype-specific genetic dependencies, our study provides a framework that guides the utility of the EC cell line models for accelerating translational research in EC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.